World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
124
Citations
87059
World Ranking
3151
National Ranking
319

Overview

John M. Goldman was a researcher affiliated with Imperial College London in the United Kingdom. Their academic work focused primarily on the field of Medicine, with particular attention to several subfields including Hematology, Genetics, Surgery, Epidemiology, and Rheumatology.

Their research contributions included studies related to chronic and acute forms of leukemia, as well as muscle and inflammatory disorders. Specific topics covered in their publications were:

  • Chronic Myeloid Leukemia Treatments
  • Acute Myeloid Leukemia Research
  • Chronic Lymphocytic Leukemia Research
  • Muscle and Compartmental Disorders
  • Inflammatory Myopathies and Dermatomyositis
  • Eosinophilic Disorders and Syndromes

John M. Goldman published multiple papers, including:

  • The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukaemia, 2022, British Journal of Haematology
  • Acute myositis secondary to Epstein-Barr virus in the absence of infectious mononucleosis with severe rhabdomyolysis, 2023, BMJ Case Reports

Their frequent co-authors included Paolo Gallipoli, Richard E. Clark, Jenny Byrne, Jane F. Apperley, and Dragana Milojković. These collaborations contributed to their work across different research topics and clinical investigations.

They published predominantly in venues such as the British Journal of Haematology and BMJ Case Reports.

Best Publications

  • Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

    Stephen G. O'Brien;François Guilhot;Richard A. Larson;Insa Gathmann

  • Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

    Brian J. Druker;François Guilhot;Stephen G. O'brien;Insa Gathmann

  • Graft-versus-leukemia reactions after bone marrow transplantation

    MM Horowitz;RP Gale;PM Sondel;JM Goldman

  • Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

    Hagop M Kantarjian;Charles Sawyers;Andreas Hochhaus;Francois Guilhot

  • European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

    Michele Baccarani;Michael W. Deininger;Gianantonio Rosti;Andreas Hochhaus

  • The molecular biology of chronic myeloid leukemia

    Michael W. N. Deininger;John M. Goldman;Junia V. Melo

  • Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

    Michele Baccarani;Giuseppe Saglio;John Goldman;Andreas Hochhaus

  • Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

    Michele Baccarani;Jorge Cortes;Fabrizio Pane;Dietger Niederwieser

  • Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study

    Charles L. Sawyers;Andreas Hochhaus;Eric Feldman;John M. Goldman

  • Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia

    Tim P. Hughes;Jaspal Kaeda;Susan Branford;Zbigniew Rudzki

  • Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.

    Moshe Talpaz;Richard T. Silver;Brian J. Druker;John M. Goldman

  • Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment

    John M. Goldman;Junia V. Melo

  • A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

    Jorge E. Cortes;D. W. Kim;J. Pinilla-Ibarz;P. Le Coutre

  • Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib

    David Marin;Alexandra Bazeos;Francois Xavier Mahon;Lina Eliasson

  • Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.

    A. Hochhaus;S. G. O'Brien;F. Guilhot;B. J. Druker

  • Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance

    François Xavier Mahon;Michael W. N. Deininger;Beate Schultheis;Jérome Chabrol

  • Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion.

    John M. Goldman;Robert Peter Gale;Mary M. Horowitz;James C. Biggs

  • T-cell depletion of HLA-identical transplants in leukemia.

    AM Marmont;MM Horowitz;RP Gale;K Sobocinski

  • The Tyrosine Kinase Inhibitor CGP57148B Selectively Inhibits the Growth of BCR-ABL–Positive Cells

    Michael W.N. Deininger;John M. Goldman;Nicholas Lydon;Junia V. Melo

  • International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib

    Michael Deininger;Stephen G O'Brien;François Guilhot;John M Goldman

Frequent Co-Authors

Jane F. Apperley
Jane F. Apperley Imperial College London
Nicholas C.P. Cross
Nicholas C.P. Cross University of Southampton
Richard Szydlo
Richard Szydlo Imperial College London
Andreas Hochhaus
Andreas Hochhaus Friedrich Schiller University Jena
Timothy P. Hughes
Timothy P. Hughes South Australian Health and Medical Research Institute
Francesco Dazzi
Francesco Dazzi King's College London
Michael W. Deininger
Michael W. Deininger University of Utah
Jorge E. Cortes
Jorge E. Cortes Augusta University
Mary M. Horowitz
Mary M. Horowitz Medical College of Wisconsin
Francois Guilhot
Francois Guilhot Grenoble Alpes University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in medicine doesn’t always mean becoming a physician. There are diverse pathways and online degrees that support healthcare careers—making entry into the field more flexible and accessible.

For those interested in health administration, options like online healthcare administration programs allow students to earn a relevant degree remotely. These programs train future leaders in hospital and clinical operations. If you want to save on tuition while earning a higher qualification, you can look for the cheapest master's in healthcare administration programs.

Those already working as nurses may want to advance their expertise. The most affordable dnp programs online prepare nurses for leadership roles or advanced clinical practice, often in a flexible and cost-effective format.

Pharmacy is another promising medical career. Students can earn a pharmacy degree online, opening doors to work in hospitals, community pharmacies, or research.

Best Scientists Citing John M. Goldman

Recently Published Articles